Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
J M Rowe

Abstract

Clinical data regarding the use of colony-stimulating factors for the treatment of acute myeloid leukemia (AML) are conflicting because of varying study conditions. Interpretation of data is affected by differences in patients' ages, induction regimens, the timing of growth factor administration, the presence of marrow hypoplasia, disease states, differences in the products used, and statistical endpoints. Most trials of granulocyte colony-stimulating factor (GM-CSF) have demonstrated a significant shortening of neutrophil recovery time and a trend toward higher rates of complete remission. Several studies have demonstrated a significant reduction in the rates of morbidity or early mortality with G-CSF or GM-CSF. In vitro data support the concept of enhancing antimicrobial activity with macrophage colony-stimulating factor or GM-CSF. The safety and potential benefit of these cytokines suggest that cytokines should be administered to patients receiving induction therapy for AML who are at high risk for therapy-related morbidity and mortality.

Citations

Nov 25, 2000·International Journal of Antimicrobial Agents·P Martino, C Girmenia
Jun 29, 2001·Transplant Infectious Disease : an Official Journal of the Transplantation Society·M Ellis
Apr 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D A StevensG A Pankey
Oct 13, 2006·Current Opinion in Infectious Diseases·A C Gilleece, L Fenelon
Apr 17, 2001·Current Opinion in Hematology·L BalducciG H Lyman
Dec 20, 2000·Antimicrobial Agents and Chemotherapy·A L BaltchL H Bopp
Jun 21, 2008·PLoS Computational Biology·Peter S KimDoron Levy
Jul 5, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·E Farmaki, E Roilides
Dec 14, 2011·Immunotherapy·Charalampos AntachopoulosEmmanuel Roilides
Feb 12, 2014·Proceedings of the National Academy of Sciences of the United States of America·Qiang ZhangSamuel J Danishefsky
Apr 2, 2009·Leukemia & Lymphoma·Pranatharthi Chandrasekar
Nov 19, 2011·Hematology/oncology Clinics of North America·Todd L Rosenblat, Joseph G Jurcic
May 27, 2005·British Journal of Haematology·Charalampos Antachopoulos, Emmanuel Roilides
Aug 26, 2006·Current Opinion in Microbiology·Liise-anne Pirofski, Arturo Casadevall
Apr 18, 2006·Seminars in Hematology·Joel Gingerich, Eric J Bow
May 20, 2003·Infectious Disease Clinics of North America·Emmanuel RoilidesStephen Chanock
Apr 30, 2003·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Emmanuel RoilidesEvangelia Farmaki
Feb 3, 2007·Expert Review of Anti-infective Therapy·Jorge GarbinoEmmanuel Roilides
May 5, 2005·Blood·Martin S TallmanJacob M Rowe
Sep 30, 2005·Journal of Medical Microbiology·Michael EllisJörgen Kristensen
Oct 26, 2000·Hospital Medicine·M Ellis, M Richardson
Apr 9, 1999·Clinical Microbiology Reviews·J P Latgé

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.